Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Employees - 1800,
CEO - Mr. Kyle W. Gano Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 10.26B
Altman ZScore(max is 10): 7.29, Piotroski Score(max is 10): 6, Working Capital: $1217000000, Total Assets: $3718700000, Retained Earnings: $29200000, EBIT: 583000000, Total Liabilities: $1129000000, Revenue: $2355299999
- Current Price $102.88 - Analyst Target Price $165.08| Ticker | NBIX |
| Index | - |
| Curent Price | 102.88 |
| Change | -5.01% |
| Market Cap | 10.26B |
| Average Volume | 1.32M |
| Income | 341.30M |
| Sales | 2.36B |
| Book Value/Share | 26.05 |
| Cash/Share | 10.79 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | Dec 29, 1995 |
| Employees | 1800 |
| Moving Avg 20days | -7.13% |
| Moving Avg 50days | -15.48% |
| Moving Avg 200days | -20.31% |
| Shares Outstanding | 99.40M |
| Earnings Date | Feb 06 AMC |
| Inst. Ownership | 94.14% |
| Price/Earnings | 31.26 |
| Forwad P/E | 16.56 |
| PE Growth | 0.82 |
| Price/Sales | 4.36 |
| Price/Book | 3.95 |
| Price/Cash | 9.53 |
| Price/FCF | 18.41 |
| Quick Ratio | 3.28 |
| Current Ratio | 3.40 |
| Debt/Equity | 0.19 |
| Return on Assets | 9.51% |
| Return on Equity | 14.16% |
| Return on Investment | 11.21% |
| Gross Margin | 97.56% |
| Ops Margin | 24.75% |
| Profit Margin | 14.49% |
| RSI | 30.06 |
| BETA(β) | 0.25 |
| From 52week Low | -2.18% |
| From 52week High | -34.88% |
| EPS | 3.29 |
| EPS next Year | 6.21 |
| EPS next Qtr | 0.77 |
| EPS this Year | 25.19% |
| EPS next 5 Year | 38.11% |
| EPS past 5 Year | 53.47% |
| Sales past 5 Year | 24.80% |
| EPS Y/Y | 33.67% |
| Sales Y/Y | 24.81% |
| EPS Q/Q | -30.61% |
| Sales Q/Q | 21.84% |
| Sales Surprise | -0.28% |
| EPS Surprise | -37.73% |
| ATR(14) | 3.37 |
| Perf Week | -9.75% |
| Perf Month | -9.64% |
| Perf Quarter | -24.63% |
| Perf Year | -25.31% |
| Perf YTD | -24.63% |
| Target Price | 165.08 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer